Text Size

Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

This study has been completed.
Sponsor:
Information provided by:
Bnai Zion Medical Center
ClinicalTrials.gov Identifier:
NCT00261937
First received: December 5, 2005
Last updated: February 5, 2013
Last verified: December 2005
History of Changes
  Purpose

We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.


Condition Intervention Phase
Bronchiolitis
 Drug: Inhaled Furosemide vs Placebo (Normal Saline)
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Resource links provided by NLM:

Drug Information available for: Furosemide
U.S. FDA Resources

Further study details as provided by Bnai Zion Medical Center:

Primary Outcome Measures:
  • Clinical respiratory effects

Secondary Outcome Measures:
  • 1. The duration of hospitalization
  • 2. Time weaned off oxygen
  • 3. Time to full enteral feeding

Study Start Date: December 2005
Study Completion Date: April 2006
  Eligibility

Ages Eligible for Study:   up to 12 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 0-12 months.
  • Infants who are otherwise healthy
  • Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately.
  • Parents signed a written informed consent.

Exclusion Criteria:

  • • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00261937

Locations
Israel
Bnai Zion Medical Center and Naharia Galilli Medical Center
Haifa, Israel, 31048
Sponsors and Collaborators
Bnai Zion Medical Center
Investigators
Principal Investigator: Amir Kugelman Bnai Zion Medical Center
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00261937     History of Changes
Other Study ID Numbers: 67/05
Study First Received: December 5, 2005
Last Updated: February 5, 2013
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Bronchiolitis
Bronchiolitis, Viral
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Virus Diseases
Furosemide
 Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 13, 2013